Clinical Infectious Diseases 2007;44:968–971
© 2007 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2007/4407-0014$15.00
DOI: 10.1086/512372
BRIEF REPORT
A Case of Naturally Acquired Inhalation Anthrax: Clinical Care and Analyses of Anti–Protective Antigen Immunoglobulin G and Lethal Factor
James J. Walsh,1
Nicki Pesik,3
Conrad P. Quinn,4
Veronica Urdaneta,2
Clare A. Dykewicz,4
Anne E. Boyer,7
Jeannette Guarner,5
Patricia Wilkins,4
Kim J. Norville,1
John R. Barr,7
Sherif R. Zaki,5
Jean B. Patel,6
Sarah P. Reagan,4
James L. Pirkle,7
Tracee A. Treadwell,3
Nancy Rosenstein Messonnier,4
Lisa D. Rotz,3
Richard F. Meyer,3 and
David S. Stephens8
1Section of Pulmonary and Critical Care Medicine, Guthrie Clinic, Sayre, and 2Division of Infectious Disease Epidemiology, Pennsylvania Department of Health, Harrisburg, Pennsylvania; and 3Bioterrorism Preparedness and Response Program and Divisions of 4Bacterial and Mycotic Diseases, 5Viral and Rickettsial Diseases, and 6Healthcare Quality Promotion, National Center for Infectious Diseases, Coordinating Center for Infectious Diseases, and 7Division of Laboratory Sciences, National Center for Environmental Health, Coordinating Center for Environmental Health and Injury Prevention, Centers for Disease Control and Prevention, and 8Emory University School of Medicine, Atlanta, Georgia
This report describes the first case of naturally acquired inhalation anthrax in the United States since 1976. The patient’s clinical course included adjunctive treatment with human anthrax immunoglobulin. Clinical correlation of serologic assays for the lethal factor component of lethal toxin and anti–protective antigen immunoglobulin G are also presented.
Received 29 September 2006; accepted 14 December 2006; electronically published 26 February 2007.
Reprints or correspondence: Dr. Nicki Pesik, Bioterrorism Preparedness and Response Program, Centers for Disease Control and Prevention, 1600 Clifton Rd., NE, Mailstop C‐18, Atlanta, GA 30333 (
NPesik@cdc.gov).
Cited by
Christian A. Schmittinger, Martin W. Dünser, Ganbat Tsenddorj. (2009) Norepinephrine in anthrax-associated shock: Even worse than figs?*.
Critical Care Medicine 37:4, 1510-1513
Online publication date: 1-May-2009.
CrossRef Nicholas J. Vietri, Bret K. Purcell, Steven A. Tobery, Suzanne L. Rasmussen, Elizabeth K. Leffel, Nancy A. Twenhafel, Bruce E. Ivins, Mark D. Kellogg, Wendy M. Webster, Mary E. Wright, and Arthur M. Friedlander. (2009) A Short Course of Antibiotic Treatment Is Effective in Preventing Death from Experimental Inhalational Anthrax after Discontinuing Antibiotics.
The Journal of Infectious Diseases 199:3, 336-341
Online publication date: 1-Feb-2009.
Sean V. Shadomy, Theresa L. Smith. (2008) Anthrax.
Journal of the American Veterinary Medical Association 233:1, 63-72
Online publication date: 1-Aug-2008.
CrossRef John D. Grabenstein. (2008) Vaccines: Countering Anthrax: Vaccines and Immunoglobulins.
Clinical Infectious Diseases 46:1, 129-136
Online publication date: 1-Jan-2008.
Yan Li, Kevin Sherer, Xizhong Cui, Peter Q Eichacker. (2007) New insights into the pathogenesis and treatment of anthrax toxin-induced shock.
Expert Opinion on Biological Therapy 7:6, 843-854
Online publication date: 1-Jul-2007.
CrossRef